{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:50:16Z","timestamp":1790203816943,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Orthop Surg Traumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Renin-angiotensin-aldosterone system (RAAS) inhibitors, including angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs), are commonly prescribed antihypertensive medications with proposed antifibrotic and bone-protective effects. Their impact on outcomes following total shoulder arthroplasty (TSA) remains unclear. This study evaluates the association between perioperative RAAS inhibitor exposure and postoperative outcomes after TSA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study using the TriNetX network identified patients undergoing primary shoulder arthroplasty (2005\u20132025), stratified by ACEi or ARB use. One-to-one propensity score matching was performed. Outcomes included 90-day medical complications and 1-year mechanical complications and revision.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Post-matching, 27,938 patients per cohort (ARB vs. control) and 30,602 per cohort (ACEi vs. control) were included. Neither ARB nor ACEi use reduced rates of manipulation under anesthesia or capsular release at one year. Both cohorts had higher 90-day rates of emergency department visits, readmission, myocardial infarction, and acute renal failure. ACEi use was additionally associated with pulmonary embolism, deep-vein thrombosis, transfusion, and sepsis. At one year, both cohorts showed higher rates of periprosthetic joint infection, aseptic loosening, and revision. Dislocation risk was increased with ACEi use only.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Perioperative RAAS inhibitor use was not associated lower rates of antifibrotic procedures following TSA. Instead, RAAS inhibitor use was associated with higher rates of several perioperative medical complications and longer-term surgical events, including infection and revision. ACE inhibitor exposure demonstrated a broader complication profile compared with ARB exposure. However, because patients receiving RAAS inhibitors often have greater comorbidity burden, these findings should be interpreted as associative rather than causal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Level of evidence III<\/jats:title>\n                    <jats:p>Retrospective Cohort Study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00590-026-04883-y","type":"journal-article","created":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T15:49:28Z","timestamp":1785599368000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Perioperative antihypertensive medication use is associated with no antifibrotic benefit but higher complications and revision rates following shoulder arthroplasty"],"prefix":"10.1007","volume":"36","author":[{"given":"Tarishi","family":"Parmar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Fiandeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Daher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akin","family":"Adio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jad","family":"Lawand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Abboud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,1]]},"reference":[{"issue":"12","key":"4883_CR1","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1016\/j.jse.2020.03.049","volume":"29","author":"ER Wagner","year":"2020","unstructured":"Wagner ER, Farley KX, Higgins I, Wilson JM, Daly CA, Gottschalk MB (2020) The incidence of shoulder arthroplasty: rise and future projections compared with hip and knee arthroplasty. J Shoulder Elb Surg 29(12):2601\u20132609. https:\/\/doi.org\/10.1016\/j.jse.2020.03.049","journal-title":"J Shoulder Elb Surg"},{"issue":"13","key":"4883_CR2","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/j.jacc.2018.01.058","volume":"71","author":"FH Messerli","year":"2018","unstructured":"Messerli FH, Bangalore S, Bavishi C, Rimoldi SF (2018) Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use? J Am Coll Cardiol 71(13):1474\u20131482. https:\/\/doi.org\/10.1016\/j.jacc.2018.01.058","journal-title":"J Am Coll Cardiol"},{"key":"4883_CR3","doi-asserted-by":"publisher","unstructured":"Thompson A, Fleischmann KE, Smilowitz NR et al (2024) AHA\/ACC\/ACS\/ASNC\/HRS\/SCA\/SCCT\/SCMR\/SVM guideline for perioperative cardiovascular management for noncardiac surgery: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. JACC 84(19):1869\u20131969. https:\/\/doi.org\/10.1016\/j.jacc.2024.06.013","DOI":"10.1016\/j.jacc.2024.06.013"},{"key":"4883_CR4","doi-asserted-by":"publisher","first-page":"175780","DOI":"10.1016\/j.ejphar.2023.175780","volume":"951","author":"W Parichatikanond","year":"2023","unstructured":"Parichatikanond W, Duangrat R, Mangmool S (2023) G\u03b1q protein-biased ligand of angiotensin II type 1 receptor mediates myofibroblast differentiation through TGF-\u03b21\/ERK axis in human cardiac fibroblasts. Eur J Pharmacol 951:175780. https:\/\/doi.org\/10.1016\/j.ejphar.2023.175780","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"4883_CR5","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.arth.2023.10.015","volume":"39","author":"JA Albright","year":"2024","unstructured":"Albright JA, Testa EJ, Ibrahim Z et al (2024) Postoperative angiotensin receptor blocker use is associated with decreased rates of manipulation under anesthesia, arthroscopic lysis of adhesions, and prosthesis-related complications in patients undergoing total knee arthroplasty. J Arthroplasty 39(4):954\u2013959e1. https:\/\/doi.org\/10.1016\/j.arth.2023.10.015","journal-title":"J Arthroplasty"},{"issue":"8S","key":"4883_CR6","doi-asserted-by":"publisher","first-page":"S1010","DOI":"10.1016\/j.arth.2022.03.026","volume":"37","author":"A Premkumar","year":"2022","unstructured":"Premkumar A, Anatone A, Illescas A et al (2022) Perioperative use of antifibrotic medications associated with lower rate of manipulation after primary TKA: an analysis of 101,366 patients. J Arthroplasty 37(8S):S1010\u2013S1015","journal-title":"J Arthroplasty"},{"issue":"6","key":"4883_CR7","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.3928\/01477447-20250909-01","volume":"48","author":"ML Carpenter","year":"2025","unstructured":"Carpenter ML, Cruz E, Hirpara A, Sidrak J, Dayton M, Hogan C (2025) Perioperative angiotensin-receptor blocker use shows decreased rates of manipulation under anesthesia and revisions after total knee arthroplasty: a systematic review. Orthopedics 48(6):e251\u2013e258. https:\/\/doi.org\/10.3928\/01477447-20250909-01","journal-title":"Orthopedics"},{"key":"4883_CR8","doi-asserted-by":"publisher","unstructured":"Lee CS, Serotte JC, Reddy S, Shi L, Maassen NH (2025) Angiotensinogen II receptor blockers may decrease risk of adhesive capsulitis after rotator cuff repair. Arthrosc Sports Med Rehabil. https:\/\/doi.org\/10.1016\/j.asmr.2025.101165","DOI":"10.1016\/j.asmr.2025.101165"},{"issue":"11","key":"4883_CR9","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1016\/j.jse.2024.02.035","volume":"33","author":"EJ Testa","year":"2024","unstructured":"Testa EJ, Callanan TC, Albright JA et al (2024) Decreased prevalence of new-onset adhesive capsulitis in patients prescribed angiotensin receptor blockers. J Shoulder Elb Surg 33(11):2427\u20132432. https:\/\/doi.org\/10.1016\/j.jse.2024.02.035","journal-title":"J Shoulder Elb Surg"},{"key":"4883_CR10","doi-asserted-by":"publisher","unstructured":"Miltenberg B, Linton A, Abe E et al (2025) Patients on losartan have similar rates of manipulation under anesthesia after total knee arthroplasty. Cureus 17(8):e89572. https:\/\/doi.org\/10.7759\/cureus.89572","DOI":"10.7759\/cureus.89572"},{"issue":"7","key":"4883_CR11","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1016\/j.arthro.2024.11.084","volume":"41","author":"B Miltenberg","year":"2025","unstructured":"Miltenberg B, Martinazzi BJ, Monahan PF et al (2025) Perioperative losartan is associated with similar rates of additional surgical procedures for postoperative shoulder stiffness after primary arthroscopic rotator cuff repair but lower rates of secondary debridement and repair. Arthrosc J Arthrosc Relat Surg 41(7):2214\u20132221. https:\/\/doi.org\/10.1016\/j.arthro.2024.11.084","journal-title":"Arthrosc J Arthrosc Relat Surg Off Publ Arthrosc Assoc N Am Int Arthrosc Assoc"},{"key":"4883_CR12","doi-asserted-by":"publisher","unstructured":"Frederick JS, Gazgalis A, Peterson JR et al (2024) ACE inhibitor use does not significantly affect occurrence of manipulation under anesthesia following total knee arthroplasty. J Orthop Exp Innov. https:\/\/doi.org\/10.60118\/001c.89993","DOI":"10.60118\/001c.89993"},{"issue":"4","key":"4883_CR13","doi-asserted-by":"publisher","first-page":"e70089","DOI":"10.1002\/jeo2.70089","volume":"11","author":"G Anzillotti","year":"2024","unstructured":"Anzillotti G, Gomoll AH, Conte P et al (2024) Limited evidence for the usage of renin\u2013angiotensin\u2013aldosterone pathway blockers to prevent arthrofibrosis after total knee arthroplasty. A systematic review of clinical evidence. J Exp Orthop 11(4):e70089. https:\/\/doi.org\/10.1002\/jeo2.70089","journal-title":"J Exp Orthop"},{"key":"4883_CR14","doi-asserted-by":"publisher","unstructured":"Zhao Z, Wang C, Xu Y et al (2021) Effects of the local bone renin-angiotensin system on titanium-particle-induced periprosthetic osteolysis. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2021.684375","DOI":"10.3389\/fphar.2021.684375"},{"issue":"2","key":"4883_CR15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1359\/jbmr.081006","volume":"24","author":"Y Asaba","year":"2009","unstructured":"Asaba Y, Ito M, Fumoto T et al (2009) Activation of renin-angiotensin system induces osteoporosis independently of hypertension. J Bone Miner Res 24(2):241\u2013250. https:\/\/doi.org\/10.1359\/jbmr.081006","journal-title":"J Bone Min Res"},{"issue":"46","key":"4883_CR16","doi-asserted-by":"publisher","first-page":"e8331","DOI":"10.1097\/MD.0000000000008331","volume":"96","author":"CI Chen","year":"2017","unstructured":"Chen CI, Yeh JS, Tsao NW et al (2017) Association between renin-angiotensin-aldosterone system blockade and future osteoporotic fracture risk in hypertensive population: a population-based cohort study in Taiwan. Medicine 96(46):e8331. https:\/\/doi.org\/10.1097\/MD.0000000000008331","journal-title":"Medicine"},{"issue":"1","key":"4883_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s11658-020-00225-w","volume":"25","author":"DY Cao","year":"2020","unstructured":"Cao DY, Saito S, Veiras LC et al (2020) Role of angiotensin-converting enzyme in myeloid cell immune responses. Cell Mol Biol Lett 25(1):31. https:\/\/doi.org\/10.1186\/s11658-020-00225-w","journal-title":"Cell Mol Biol Lett"},{"issue":"50","key":"4883_CR18","doi-asserted-by":"publisher","first-page":"39051","DOI":"10.1074\/jbc.M110.163782","volume":"285","author":"D Okwan-Duodu","year":"2010","unstructured":"Okwan-Duodu D, Datta V, Shen XZ et al (2010) Angiotensin-converting enzyme overexpression in mouse myelomonocytic cells augments resistance to Listeria and methicillin-resistant Staphylococcus aureus*. J Biol Chem 285(50):39051\u201339060. https:\/\/doi.org\/10.1074\/jbc.M110.163782","journal-title":"J Biol Chem"},{"key":"4883_CR19","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.3389\/fimmu.2020.01919","volume":"11","author":"R Trikha","year":"2020","unstructured":"Trikha R, Greig D, Kelley BV et al (2020) Inhibition of angiotensin converting enzyme impairs anti-staphylococcal immune function in a preclinical model of implant infection. Front Immunol 11:1919. https:\/\/doi.org\/10.3389\/fimmu.2020.01919","journal-title":"Front Immunol"},{"key":"4883_CR20","doi-asserted-by":"publisher","first-page":"101641","DOI":"10.1016\/j.artd.2025.101641","volume":"32","author":"R Trikha","year":"2025","unstructured":"Trikha R, Cevallos N, Zhang AL et al (2025) Angiotensin-converting enzyme inhibition as a potential risk factor for periprosthetic joint infection following total knee arthroplasty. Arthroplasty Today 32:101641. https:\/\/doi.org\/10.1016\/j.artd.2025.101641","journal-title":"Arthroplasty Today"},{"issue":"5","key":"4883_CR21","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/jhm.2203","volume":"9","author":"V Chopra","year":"2014","unstructured":"Chopra V, Wijeysundera DN (2014) The right time and Pl ACE: optimal management of perioperative angiotensin-converting enzyme inhibitors. J Hosp Med 9(5):334\u2013336. https:\/\/doi.org\/10.1002\/jhm.2203","journal-title":"J Hosp Med"},{"issue":"2","key":"4883_CR22","doi-asserted-by":"publisher","first-page":"86","DOI":"10.2344\/anpr-67-02-02","volume":"67","author":"T Hojo","year":"2020","unstructured":"Hojo T, Shibuya M, Kimura Y, Otsuka Y, Fujisawa T (2020) Refractory hypotension during general anesthesia despite withholding telmisartan. Anesth Prog 67(2):86\u201389. https:\/\/doi.org\/10.2344\/anpr-67-02-02","journal-title":"Anesth Prog"},{"issue":"5","key":"4883_CR23","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1161\/01.CIR.95.5.1115","volume":"95","author":"B Hornig","year":"1997","unstructured":"Hornig B, Kohler C, Drexler H (1997) Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 95(5):1115\u20131118. https:\/\/doi.org\/10.1161\/01.CIR.95.5.1115","journal-title":"Circulation"},{"key":"4883_CR24","doi-asserted-by":"publisher","first-page":"107414","DOI":"10.1016\/j.vph.2024.107414","volume":"156","author":"MZ Siti-Zubaidah","year":"2024","unstructured":"Siti-Zubaidah MZ, Harafinova HS, Liba AN, Nordin ML, Hambali KA, Siti HN (2024) Exploring bradykinin: a common mediator in the pathophysiology of sepsis and atherosclerotic cardiovascular disease. Vascul Pharmacol 156:107414. https:\/\/doi.org\/10.1016\/j.vph.2024.107414","journal-title":"Vascul Pharmacol"},{"issue":"6","key":"4883_CR25","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/hr.2014.22","volume":"37","author":"T Sakamoto","year":"2014","unstructured":"Sakamoto T, Kudoh T, Sakamoto K, Matsui K, Ogawa H (2014) Antithrombotic effects of losartan in patients with hypertension complicated by atrial fibrillation: 4A (Angiotensin II Antagonist of platelet Aggregation in patients with Atrial fibrillation), a pilot study. Hypertens Res 37(6):513\u2013518. https:\/\/doi.org\/10.1038\/hr.2014.22","journal-title":"Hypertens Res"},{"issue":"3","key":"4883_CR26","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1152\/physiol.00036.2020","volume":"36","author":"JM Saavedra","year":"2021","unstructured":"Saavedra JM (2021) Angiotensin receptor blockers are not just for hypertension anymore. Physiology 36(3):160\u2013173. https:\/\/doi.org\/10.1152\/physiol.00036.2020","journal-title":"Physiology"},{"issue":"1","key":"4883_CR27","doi-asserted-by":"publisher","first-page":"e87813","DOI":"10.1371\/journal.pone.0087813","volume":"9","author":"YK Chae","year":"2014","unstructured":"Chae YK, Khemasuwan D, Dimou A et al (2014) Inhibition of renin angiotensin axis may be associated with reduced risk of developing venous thromboembolism in patients with atherosclerotic disease. PLoS ONE 9(1):e87813. https:\/\/doi.org\/10.1371\/journal.pone.0087813","journal-title":"PLoS ONE"}],"container-title":["European Journal of Orthopaedic Surgery &amp; Traumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00590-026-04883-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00590-026-04883-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00590-026-04883-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T15:49:29Z","timestamp":1785599369000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00590-026-04883-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4883"],"URL":"https:\/\/doi.org\/10.1007\/s00590-026-04883-y","relation":{},"ISSN":["1432-1068"],"issn-type":[{"value":"1432-1068","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]},"assertion":[{"value":"14 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were performed in compliance with relevant laws and institutional guidelines. De-identified patient data from TrinetX is exempt from IRB Approval.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"314"}}